Hanmi Pharm. Co., Ltd. (KRX:128940)
462,000
+40,000 (9.48%)
Nov 20, 2026, 1:05 PM KST
Hanmi Pharm. Revenue
Hanmi Pharm. had revenue of -482.77B KRW in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to 1.56T, up 6.58% year-over-year. In the year 2025, Hanmi Pharm. had annual revenue of 1.55T with 3.48% growth. That makes Hanmi Pharm. the 6,962nd largest company in the world by revenue and 307th in South Korea.
Revenue (ttm)
1.56T
Revenue Growth
+6.58%
P/S Ratio
3.75
Revenue / Employee
625.55M
Employees
2,338
Market Cap
5.86T
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Hanmi Pharm. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55T | 52.03B | 3.48% |
| Dec 31, 2024 | 1.50T | 4.61B | 0.31% |
| Dec 31, 2023 | 1.49T | 159.34B | 11.97% |
| Dec 31, 2022 | 1.33T | 128.36B | 10.67% |
| Dec 31, 2021 | 1.20T | 127.33B | 11.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Yuhan | 2.28T |
| Daewoong | 2.17T |
| GC Biopharma | 1.96T |
| Chong Kun Dang Pharmaceutical | 1.78T |
| Daewoong Pharmaceutical | 1.68T |
| Dong-A Pharmaceutical | 1.52T |
| Boryung | 1.06T |
| JW Pharmaceutical | 820.86B |
Hanmi Pharm. News
- 4 months ago - Hanmi Pharma Completes Aptose Biosciences Acquisition; Stock Up - Nasdaq